UNCY - Unicycive Therapeutics, Inc Total Debt to Capital

Unicycive Therapeutics (UNCY) focuses on developing urinary system therapies, integrating sustainability principles and ethical standards into its research. Business efficiency relies on a streamlined distribution of medications to medical centers. The current debt-to-equity ratio stands at 0.01, with development funded by existing reserves. This price chart, which assists in the baseline asset valuation, clearly demonstrates the company's financial condition.

This ratio determines the degree of financial leverage by comparing total liabilities to net asset value to assess the stability of the capital structure. By analyzing the current debt-to-equity ratio, an investor can discern Unicycive Therapeutics (UNCY) dependence on creditors, which is critical when financing the robotization of laboratory platforms and the automation of small molecule screening for the study of renal pathologies.